Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Copyright restrictions prevent us from including PDFs of our papers on this website. Most EBCTCG papers are free to download from the relevant journal website but you may need to register or have an online subscription.

You may need to download Adobe Reader to view PDFs. If you use Mozilla Firefox, and see the warning 'This PDF document might not be displayed correctly' choose to 'Open With Different Viewer'.

Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. Lancet 2023; 402: 1991-2003; DOI: 10.1016/S0140-6736(23)01082-6. Published online November 03, 2023. 

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials  (Lancet 2023; 401: 1277-1292 DOI: 10.1016/S0140-6736(23)00285-4)

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials (Lancet Oncol 2022; 23:382-392, DOI: 10.1016/S1470-2045(21)00758-0)

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (Lancet Oncol 2021; 22: 1139-1150, DOI: 10.1016/S1470-2045(21)00288-6)

 Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (Lancet 2019; 393: 1440-52, DOI: 10.1016/S0140-6736(18)33137-4)

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

(Lancet Oncol 2018; 19: 27-39, DOI: 10.1016/S1470-2045(17)30777-5)

20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years
(N Engl J Med 2017; 377: 1836-1846, DOI: 10.1056/NEJMoa1701830)

Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials 
(J Clin Oncol 2017; 
35: 1641-49, DOI: 10.1200/JCO.2016.72.0722)

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 
(Lancet 2015; 386: 1353-61, DOI: 10.1016/S0140-6736(15)60908-4)

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials 
(Lancet 2015; 386: 1341-52, DOI: 10.1016/S0140-6736(15)61074-1)

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials 
(Lancet 2014; 
383: 2127-35, DOI: 10.1016/S0140-6736(14)60488-8)

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
(Lancet 2012; 379: 432-44, DOI:10.1016/S0140-6736(11)61625-5)

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials 
(Lancet 2011; 
378: 1707-60, DOI:10.1016/S0140-6736(11)61629-2)

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials 
(Lancet 2011; 
378: 771-84, DOI:10.1016/S0140-6736(11)60993-8)

Overview of the randomised trials of radiotherapy in ductal carcinoma in situ (DCIS) of the breast 
(J Natl Cancer Inst Monogr 2010; 
41: 162-177. DOI: 10.1093/jncimonographs/lgq039)

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials 
(The Lancet 2008; 
371: 29-40, DOI: 10.1016/S0140-6736(08)60069-0)

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and on 15-year survival: an overview of the randomised trials 
(The Lancet 2005; 366: 2087-2106, DOI: 10.1016/S0140-6736(05)67887-7)

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials 
(The Lancet 2005; 365: 1687-1717, DOI: 10.1016/S0140-6736(05)66544-0)